Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

CT-868

A Study of CT-868 in Type 1 Diabetes Mellitus

Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 111

NCT06062069

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
CT-868 Low Dosen/rn/rn/rn/rn/r
CT-868 Medium Dosen/rn/rn/rn/rn/r
CT-868 High Dosen/rn/rn/rn/rn/r
CT-868 Placebo2 participants0 participants2 participantsn/r0
Arm 2: CT-868 Titrated to 1.8 mg13 participants4 participants6 participantsn/r0
Arm 3: CT-868 Titrated to 4.1 mg17 participants8 participants6 participantsn/r0
Arm 4: CT-868 Titrated to 6.6 mg9 participants8 participants6 participantsn/r0

A count stays a count. This page does not turn a count into a percent.